



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Pinzon-Charry, A;Maxwell, T;McGuckin, MA;Schmidt, C;Furnival, C;López, JA

Title:

Spontaneous apoptosis of blood dendritic cells in patients with breast cancer

Date:

2005-12-16

Citation:

Pinzon-Charry, A., Maxwell, T., McGuckin, M. A., Schmidt, C., Furnival, C. & López, J. A. (2005). Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. *Breast Cancer Research*, 8 (1), pp.R5-. <https://doi.org/10.1186/bcr1361>.

Persistent Link:

<https://hdl.handle.net/11343/255965>

License:

CC BY

Research article

Open Access

Spontaneous apoptosis of blood dendritic cells in patients with breast cancerAlberto Pinzon-Charry^{1,2}, Tammy Maxwell¹, Michael A McGuckin^{2,3}, Chris Schmidt¹, Colin Furnival⁴ and J Alejandro López^{1,2}¹Dendritic Cell and Cancer Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland, Australia²School of Medicine, University of Queensland, Brisbane, Queensland, Australia³Mater Medical Research Institute, Brisbane, Queensland, Australia⁴Wesley Medical Centre, Brisbane, Queensland, AustraliaCorresponding author: Alberto Pinzon-Charry, albertoP@qimr.edu.au

Received: 3 Sep 2005 Revisions requested: 18 Oct 2005 Revisions received: 24 Oct 2005 Accepted: 1 Nov 2005 Published: 16 Dec 2005

Breast Cancer Research 2006, **8**:R5 (doi:10.1186/bcr1361)This article is online at: <http://breast-cancer-research.com/content/8/1/R5>© 2005 Pinzon-Charry *et al.*; licensee BioMed Central Ltd.This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.**Abstract**

Introduction Dendritic cells (DCs) are key antigen-presenting cells that play an essential role in initiating and directing cellular and humoral immunity, including anti-tumor responses. Due to their critical role in cancer, induction of DC apoptosis may be one of the central mechanisms used by tumors to evade immune recognition.

Methods Spontaneous apoptosis of blood DCs (lineage negative HLA-DR positive cells) was assessed in peripheral blood mononuclear cells (PBMCs) using Annexin-V and TUNEL assays immediately after blood collection. The role of tumor products was assessed by culturing cells with supernatants derived from breast cancer cell lines (TDSN) or PBMCs (PBMC-SN, as a control). The capacity of DC stimulation to prevent apoptosis was assessed by incubating DC with inflammatory cytokines, poly I:C, IL-12 or CD40 ligand (CD40L) prior to culture with TDSN. Apoptosis was determined by flow cytometry and microscopy, and Bcl-2 expression determined by intracellular staining.

Results In this study we document the presence of a significantly higher proportion of apoptotic (Annexin-V⁺ and TUNEL⁺) blood DCs in patients with early stage breast cancer

(stage I to II; n = 13) compared to healthy volunteers (n = 15). We examined the role of tumor products in this phenomenon and show that supernatants derived from breast cancer lines induce apoptosis of blood DCs in PBMC cultures. Aiming to identify factors that protect blood DC from apoptosis, we compared a range of clinically available maturation stimuli, including inflammatory cytokines (tumor necrosis factor- α , IL-1 β , IL-6 and prostaglandin (PG)E₂ as a cytokine cocktail), synthetic double-stranded RNA (poly I:C) and soluble CD40 ligand. Although inflammatory cytokines and poly I:C induced robust phenotypic maturation, they failed to protect blood DCs from apoptosis. In contrast, CD40 stimulation induced strong antigen uptake, secretion of IL-12 and protected blood DCs from apoptosis through sustained expression of Bcl-2. Exogenous IL-12 provided similar Bcl-2 mediated protection, suggesting that CD40L effect is mediated, at least in part, through IL-12 secretion.

Conclusion Cumulatively, our results demonstrate spontaneous apoptosis of blood DCs in patients with breast cancer and confirm that *ex vivo* conditioning of blood DCs can protect them from tumor-induced apoptosis.

Introduction

Dendritic cells (DCs) are bone marrow-derived leukocytes specialized in antigen presentation [1]. They play an essential

role in initiating and directing cellular and humoral immunity, including antitumor responses. Tumor production of immunosuppressive factors (cytokines, arachidonic acid metabolites, glycosphingolipids, polyamines) with detrimental effects on DC maturation and function can significantly prevent the

APC = allophycocyanin; CC = cytokine cocktail; DC = dendritic cell; FACS = fluorescence activated cell sorting; FITC = fluorescein isothiocyanate; FSC = Forward side characteristic; IL = interleukin; Lin = lineage markers; Lin⁻HLA-DR⁺ = lineage negative HLA-DR positive; PBMC = peripheral blood mononuclear cell; PBMC-SN = PBMC-conditioned supernatant; PBS = phosphate-buffered saline; PE = phycoerythrin; PG = prostaglandin; SSC = side scatter characteristic; TDSN = tumor-derived supernatant; TNF = tumor necrosis factor; TLR = Toll-like receptor; Δ MFI = delta mean fluorescence intensity; 7-AAD = 7-Aminoactinomycin D.

establishment of effective antitumor immune responses [2]. Recent evidence has indicated that induction of apoptosis in immune cells is yet another mechanism used by tumors to evade immune recognition [3]. Indeed, several studies have demonstrated that DCs undergo apoptosis after interacting with cancer cells or tumor-derived factors *in vitro* [4-7]. However, these studies have used DCs generated *in vitro* following prolonged culture with cytokines and cytokine-driven activity may not reflect the functional status of DC populations circulating *in vivo*.

In vivo circulating blood DCs are identified by their high expression of HLA-DR and lack of specific lineage markers (CD3, CD14, CD19, CD20, CD56 and CD34) found on other leukocytes [8]. DCs freshly isolated from blood offer the theoretical advantage of being in their natural state of differentiation, free from the influence of exogenous cytokines, more responsive and presumably capable of stimulating immune responses in a more physiological manner. Hence, there is active interest in using blood DCs as vectors for cancer immunotherapy, with preliminary reports confirming their clinical potential [9,10].

Several studies, however, have demonstrated severe phenotypic and functional impairment of DCs in patients with breast cancer [11,12]. Tumor-infiltrating DCs are neither mature nor activated [13,14] and blood DCs express low levels of costimulatory molecules [11,12] and IL-12 [15] and exhibit an impaired capacity to stimulate T-cells [11,12]. In this context, knowledge of the mechanisms responsible for tumor-induced DC defects in breast cancer is essential to overcome DC dysfunction and to harness their immunotherapeutic potential. Recent reports revealed spontaneous apoptosis of several subpopulations of peripheral blood mononuclear cells (PBMCs; T-cells, B-cells and monocytes) in patients with cancer [16-18]. Those findings together with the reported decreased DC function prompted us to assess the extent of spontaneous apoptosis in blood DCs from patients with breast cancer and to identify clinically available factors to protect blood DCs against tumor-induced apoptosis.

Materials and methods

Patients and donors

Thirteen female patients, 40 to 75 years of age, with histologically confirmed breast adenocarcinoma were enrolled in the study. All patients presented with early disease (stage I to II), were newly diagnosed and had received no prior cancer therapy. Staging was performed in accordance with the International Union Against Cancer, UICC TNM Classification [19]. In addition, 15 healthy female donors, 24 to 73 years of age, volunteered for the study and served as controls. The Australian Red Cross Blood Service, Brisbane, provided buffy coats. The research ethics committees of both the clinical (Wesley Medical Centre and Royal Brisbane and Women Hospital) and sci-

entific (Queensland Institute of Medical Research) institutions approved the study protocols.

Monoclonal antibodies, reagents and cytokines

The following monoclonal antibodies were used in this study: CD3, CD14, CD19, CD20, CD56, CD34, HLA-DR, CD80, CD86, tumor necrosis factor (TNF)- α and IgG1, IgG2a and IgG2b isotype controls from BD Pharmingen (BD Biosciences, San Jose, CA, USA); HLA-DR, CD40, CD83, CD19 and IgG1 isotype control from Beckman Coulter (Fullerton, CA, USA); and IL-10 and IL-12 from Caltag laboratories (Burlingame, CA, USA). All antibodies were used as the fluorescein isothiocyanate (FITC), phycoerythrin (PE), biotin, allophycocyanin (APC) or PE-Cy5 conjugate. The PE-conjugated Bcl-2 antibody reagent kit was purchased from BD Pharmingen. Complete media included RPMI 1640 supplemented with 10% fetal calf serum, penicillin (100 u/ml), streptomycin (100 μ g/ml), L-glutamine (2 mM), HEPES (25 mM) and non-essential amino acids all purchased from Gibco Life Technologies (Gaithersburg, MD, USA). The combination of pro-inflammatory cytokines consisted of IL-1 β (10 ng/ml), IL-6 (10 ng/ml) and TNF- α (10 ng/ml) obtained from R&D systems (Minneapolis, MN, USA) plus Prostaglandin E2 (PGE2, 1 μ g/ml) from Sigma (St Louis, MI, USA). Double stranded RNA (poly I:C, 50 μ g/ml) [20] was purchased from Sigma; IL-12 (100 ng/ml) was purchased from Mabtech (Stockholm, Sweden) and soluble human recombinant CD40-ligand (CD40L; 2 μ g/ml) was kindly provided by Amgen (Seattle, WA, USA).

Determination of apoptosis

Venous blood obtained from patients and volunteers was collected in heparinized tubes. Samples were processed and PBMCs recovered by Ficoll-Hypaque centrifugation. To determine the proportion of apoptotic cells, Annexin-V binding and TUNEL assays were performed after blood collection. In all experiments, each patient was tested in parallel with at least one healthy volunteer. Annexin-V binding assays were performed using the Annexin-V kit (BD Pharmingen). Briefly, PBMCs were adjusted to 10⁶ cells/ml and stained with a mixture of lineage markers (CD3, CD14, CD19, CD20, CD56, CD34) and HLA-DR for 20 minutes at 4°C. CD34 was added to the lineage mixture to exclude circulating hematopoietic stem cells. Cells were washed and resuspended in binding buffer prior to incubating with Annexin-V and 7-Aminoactinomycin D (7-AAD) for 15 minutes at room temperature. Samples were analyzed by fluorescence activated cell sorting (FACS) within one hour of staining. The TUNEL assay was performed using the Apo-BrDU-Red DNA fragmentation assay kit (BioVision, Mountain View, CA, USA). As above, PBMCs were adjusted to 10⁶ cells/ml, stained for surface markers, fixed with 1% (w/v) paraformaldehyde and resuspended in ice-cold 70% ethanol for 30 minutes prior to incubation with DNA labeling and antibody solutions according to the manufacturer's instructions. Samples were analyzed within one hour of staining. In all experiments, 5 to 10 \times 10⁵ events were collected

within the mononuclear cell gate. Data were acquired on a FACS Calibur flow cytometer and analyzed using CellQuest 3.1 (BD Bioscience), FloJo (TreeStar, San Carlos, CA, USA) or Summit (DakoCytomation, Fort Collins, CO, USA) software.

Tumor-derived supernatants

The breast cancer cell lines MCF7, MB435 and SKBR3 were sourced from the American Type Culture Collection (ATCC, Manassas, VA, USA). The MA11 line was a generous gift of Dr Phil Rye (Norwegian Radium Hospital, Oslo, Norway). Tumor-derived supernatants (TDSN) were prepared by seeding 10^7 tumor cells in 20 ml of complete medium and incubating for 72 h. Before passage, culture supernatants were collected, centrifuged to remove cells, dialyzed against fresh medium (24 to 48 h at 4°C in the dark) to replenish nutrients and stored at -20°C. Dialysis membranes (membracell, Polylabo, Strasborg, France) with a molecular weight cut-off of 10,000 to 14,000 were used. For each experiment, PBMCs were cultured (10^7 cells/ml) for 24 h in the presence of 50% (v/v) TDSN or PBMC-conditioned supernatant (PBMC-SN) as a control. Cells were harvested, washed and apoptosis in lineage negative HLA-DR positive (Lineage (Lin)⁻HLA-DR⁺) cells determined using Annexin-V binding and TUNEL assays. For morphological analysis following culture with TDSN, viable (7-AAD negative) Lin⁻HLA-DR⁺ cells were sorted (99% purity) using a MoFlo Sorter (DakoCytomation), resuspended in complete medium and cyto-centrifuged. Histology was performed on cytopspin preparations made by seeding 2 to 3×10^4 sorted cells onto a glass slide. These were air-dried and stained using May-Grunwald-Giemsa.

Phenotypic maturation, cytokine secretion and Bcl-2 expression

Four-color flow cytometry was used to analyze the phenotype and cytokine secretion of Lin⁻HLA-DR⁺ cells. Briefly, PBMCs were cultured (10^7 cells/ml) in 6-well plates for 18 to 36 h in complete medium in the presence of inflammatory cytokines (a cytokine cocktail (CC) containing IL-1 β (10 ng/ml), IL-6 (10 ng/ml), TNF- α (10 ng/ml) plus PGE₂ (1 μ g/ml)), poly I:C (50 μ g/ml) or CD40L (2 μ g/ml) and subsequently stained for flow cytometric analysis. Doses and incubation times were optimized in preliminary experiments. For cytokine secretion, 10^7 PBMCs were cultured with the CC, poly I:C or CD40L (in addition to IFN- γ and IL-1 β) in the presence of brefeldin-A (10 μ g/ml; Sigma). Cells were stained for surface markers, fixed with 1% w/v paraformaldehyde and stained with cytokine-specific monoclonal antibodies (TNF- α , IL-10 and IL-12) in 0.2% w/v saponin/PBS at 4°C overnight. For determination of Bcl-2 expression, 10^6 PBMCs were stained for surface markers (CD3, CD14, CD19, CD20, CD56, CD34 and HLA-DR), fixed with 1% w/v paraformaldehyde and stained with anti-Bcl-2 or isotype control in 0.2% w/v saponin/PBS at 4°C overnight. In all experiments, 5 to 10×10^5 events were collected within the mononuclear cell gate. Data were acquired on a FACS Calibur

flow cytometer and analyzed using CellQuest 3.1 (BD Bioscience), FloJo (TreeStar) or Summit (Cytomation) software.

Statistical analysis

Comparisons of samples to establish statistical significance were determined by the two tailed Students' t-test or one way analysis of variance (ANOVA) followed by Bonferroni's comparison test. Results were considered to be statistically significant when the *p*-value was <0.05.

Results


Spontaneous apoptosis of blood dendritic cells in patients with breast cancer

In accordance with the published literature [11-14], we also confirmed that there is significant DC dysfunction in patients with breast cancer prior to therapy (Additional file 1). Given that apoptotic DCs are ineffective at inducing immunity, here we examined the presence of apoptotic DCs obtained from patients with breast cancer (stage I to II; *n* = 13) compared to age-matched healthy females (*n* = 15). In order to include all cells undergoing apoptosis, gating was set as described in Fig. 1a. This strategy of double gating confirmed the viability of all cells while eliminating acellular debris. Blood DCs were identified as Lin⁻HLA-DR⁺ cells and apoptosis was assessed using Annexin-V and TUNEL assays. The minimal proportion of spontaneously apoptotic blood DCs in healthy volunteers was significantly increased in patients with breast cancer (*p* < 0.05 and *p* < 0.01, respectively) (Fig. 1b,c).

Apoptosis in blood dendritic cells is induced by tumor derived supernatants

Given that significantly less apoptosis was observed in samples from healthy volunteers, we hypothesized that tumor products were responsible for the elevated proportion of apoptotic blood DCs in patients with breast cancer. To more accurately examine this hypothesis, we used an *in vitro* model of blood DC culture in the absence of exogenous cytokines [21]. For this purpose, PBMCs were incubated in the presence of TDSN and apoptosis measured in Lin⁻HLA-DR⁺ cells. Incubation with PBMC-SN served as a control. All supernatants were filtered and dialyzed against fresh medium prior to use. This approach excluded the possibility of apoptosis induced by nutrient depletion. Analysis of Annexin-V binding and TUNEL assays in different cultures revealed minimal apoptosis on fresh samples and less than 10% apoptosis following culture with PBMC-SN (Fig. 2a,b). On the other hand, incubation with TDSN resulted in a significant (*p* < 0.05) increase in the proportion of apoptotic Lin⁻HLA-DR⁺ cells. Moreover, morphological evaluation frequently demonstrated features of apoptotic death in cultures containing TDSN (Fig. 2c). These data suggest that factors derived from breast cancer cell lines induce apoptotic death of Lin⁻HLA-DR⁺ cells.

Figure 1



Spontaneous apoptosis of blood dendritic cells (DCs) in patients with breast cancer. Peripheral blood mononuclear cells isolated from patients with breast cancer (stage I to II; $n = 13$) and age-matched healthy volunteers ($n = 15$) were analyzed for apoptosis by flow cytometry. **(a)** In order to include all apoptotic cells and avoid debris, gating was set to include only 7-AAD negative events (R1) which were then visualized and re-gated on forward (FSC) and side scatter (SSC) characteristics (R2). Within this mononuclear cell population, blood DCs were identified as lineage negative HLA-DR positive cells (R3). Representative dot plots are shown. **(b)** Apoptosis in blood DCs from patients (black) and healthy volunteers (grey) was determined by two different methods, Annexin-V binding and TUNEL assays. In all experiments, each patient was tested in parallel with at least one healthy volunteer. Representative histograms are shown. **(c)** Summary of apoptosis data. The proportions of Annexin-V⁺ and TUNEL⁺ blood DCs estimated for all patients (black) and healthy volunteers (grey) are shown accordingly. Error bars indicate the standard error of the mean. Statistically significant differences between controls and patients are indicated as: *, $p < 0.05$; **, $p < 0.01$.

CD40 stimulation protects blood dendritic cells against TDSN-induced apoptosis

It has recently been demonstrated that protection of DCs from apoptosis can improve antitumor immunity *in vivo* [22]. Therefore, the identification of factors that protect blood DCs against tumor-induced apoptosis could enhance their potential for immunotherapy. Analysis of Annexin-V binding revealed that pre-incubation with a CC did not decrease apoptosis in blood DCs whereas poly I:C stimulation induced a modest (not significant) reduction in apoptosis (Fig. 3). In contrast, incubation with CD40L demonstrated a significant ($p < 0.05$) decrease of TDSN-induced apoptosis to levels seen in control cultures. These data show that CD40 stimulation leads to increased resistance of blood DCs to TDSN-induced apoptosis.

Effects of IL-12 on TDSN-induced apoptosis


Due to the differential effects of inflammatory mediators on DC apoptosis, we assessed the functional maturation induced on Lin⁺HLA-DR⁺ cells following stimulation with a CC, poly I:C or

CD40L. All maturation stimuli induced significant increases in the expression of HLA-DR and co-stimulatory molecules (CD40, CD80, CD83 and CD86) (Fig. 4a). The cytokine secretion profile, however, was markedly different between stimuli. While the CC induced minimal cytokine secretion, poly I:C induced moderate secretion of TNF- α as well as IL-12. On the other hand, CD40 ligation induced modest secretion of TNF- α and robust production of IL-12. Given that IL-12 has been reported to protect *in vitro*-derived DCs from apoptosis induced by co-culture with prostate cancer cells [23], we examined whether IL-12 could protect blood DCs from apoptosis induced by breast tumor-derived supernatants. Exogenous IL-12 significantly ($p < 0.05$) reduced blood DC apoptosis (Fig. 4b), indicating that IL-12 also has a protective role against tumor-induced apoptosis.

Sustained expression of Bcl-2 correlates with protection

Given that members of the Bcl-2 family of proteins are involved in the regulation of tumor-induced apoptosis in DCs derived *in vitro* [7], we examined whether protection from TDSN-induced

Figure 2



Apoptosis in blood dendritic cells (DCs) is induced by breast tumor-derived supernatants. **(a)** Apoptosis in blood DCs was determined by Annexin-V binding and TUNEL assays following culture (24 h) in the presence of 50% (v/v) peripheral blood mononuclear cell (PBMC)-derived supernatant (PBMC-SN) or tumor-derived supernatants (TDSN; MCF7, MB435, MA11 and SKBR3). Representative dot plots (SSC on y-axis versus apoptosis on x-axis) are shown with numbers indicating the percentage of apoptotic cells. **(b)** Summary of apoptosis data. The proportions of Annexin-V⁺ and TUNEL⁺ blood DCs represent the average \pm standard error of the mean of five independent experiments for which statistically significant differences compared to PBMC-SN are shown: *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$. **(c)** For morphological analyses (original magnification times 1,000), 50 cells were assessed in three separate fields. In contrast to PBMC-SN, cultures incubated with TDSN (MA11) frequently demonstrated features of apoptotic death in blood DCs (reduction in cell volume and nuclear size, cytoplasmic blebbing, cell membrane convolutions and formation of apoptotic bodies). Three independent experiments with similar findings were performed.


apoptosis could be mediated by modulation of the expression of the anti-apoptotic protein Bcl-2. We found that incubation of cells with TDSN, but not PBMC-SN, resulted in significant ($p < 0.05$) down-regulation of Bcl-2 expression in blood DCs (Fig. 5a,b). Interestingly, pre-incubation of cells with the CC or poly I:C did not significantly change the reduction of Bcl-2 expression caused by tumor supernatants (Fig. 5b). In contrast, pre-incubation with IL-12 or CD40L resulted in sustained expression of Bcl-2, abrogating the suppressive effect induced by the TDSN (Fig. 5b). In fact, comparable levels of Bcl-2 expression were observed on fresh samples or following culture with CD40L (Fig. 5b). These data suggest loss of Bcl-2 is involved in blood DC apoptosis induced by TDSN and that protection from TDSN-induced apoptosis (as shown for

CD40L and IL-12) involves sustained expression of this molecule.

Discussion

In this study, we document the presence of a significantly higher percentage of apoptotic blood DCs in patients with breast cancer compared to healthy volunteers, suggesting that in these patients, a higher proportion of blood DCs are programmed *in vivo* to undergo apoptosis. This phenomenon appeared to be related to their cancer as all patients were newly diagnosed (no prior therapy) and no comparable apoptosis was observed in blood DCs from healthy volunteers. Although previous reports have described increased apoptosis in tumor-infiltrating DCs in patients with melanoma and

Figure 3




CD40 stimulation protects blood dendritic cells (DCs) against tumor-derived supernatant (TDSN)-induced apoptosis. TDSN-induced apoptosis in blood DCs was determined by Annexin-V binding following incubation (24 h) in the presence or absence of: (a) a combination of inflammatory cytokines (tumor necrosis factor- α , IL-1 β , IL-6 and prostaglandin (PG)E₂ as a cytokine cocktail (CC)); (b) synthetic double-stranded RNA (poly I:C); or (c) CD40 ligand (CD40L) prior to culture (24 h) with 50% (v/v) peripheral blood mononuclear cell-conditioned supernatant (PBMC-SN) or TDSN (MA11, MB435, MCF7 and SKBR3). Representative dot plots (SSC on y-axis versus apoptosis on x-axis) are shown with numbers indicating the percentage of apoptotic cells. Five independent experiments were performed for which p-values are indicated.

ovarian cancer [7], our findings clearly indicate that the inhibitory influence of the tumor extends far beyond the tumor micro-environment. In keeping with this, previous studies [16,17] have described spontaneous apoptosis of several mononuclear cell subsets (T and B lymphocytes, NK cells and monocytes) in blood of patients with different types of cancer, suggesting a rather generalized phenomenon. This, however, is the first description of spontaneous apoptosis in DCs from the peripheral blood of patients with cancer.

The physiological and clinical significance of blood DC apoptosis in patients with cancer is of substantial interest. Circulating DCs are essential for adequate immunity given that they continually replenish the pool of tissue-residing DCs and play a critical role in shaping immune responses *in vivo* [1]. Indeed, most circulating DCs appear to be *en route* from the bone marrow to peripheral and lymphoid tissues or from non-lymphoid tissues to the regional lymph nodes and spleen [24,25]. Given that apoptotic cells are rapidly cleared from the circula-

tion by the reticulo-endothelial system, our observation of a higher fraction of blood DCs undergoing apoptosis in patients with breast cancer suggests increased turnover of these cells *in vivo*. If this assumption is correct, continual efforts to replace the pool of blood DCs from bone marrow would impose chronic stress on the immune system of breast cancer patients, resulting in a relative paucity of DCs in the circulation [15,26] as well as a failure to effectively replenish DCs that infiltrate breast tumor tissue [13,14] or in the ability of DC to migrate to lymphoid organs [12] for the initiation of T-cell immunity. Accordingly, in patients with operable breast carcinoma, blood DC numbers are significantly reduced over prolonged periods of time (approximately 48 weeks post surgery) independently of other blood cell counts (monocytes, neutrophils, platelets), suggesting diminished availability of DC precursors in these patients (A Pinzon-Charry *et al.*, unpublished observations). Moreover, in a cohort of 35 patients with early (stage I and II) and advanced (stage IV) breast cancer (stage I, n = 17; stage II, n = 10; stage IV, n = 8), we found

Figure 4



Protective effect of IL-12 on tumor-derived supernatant (TDSN)-induced apoptosis. **(a)** Expression of HLA-DR and co-stimulatory molecules (CD40, CD80, CD83 and CD86) as well as secretion of cytokines (tumor necrosis factor (TNF)- α , IL-10 and IL-12) was determined for blood DCs following stimulation (24 h) with a cytokine cocktail (CC), synthetic double-stranded RNA (poly I:C) or CD40 ligand (CD40L) as described in Materials and methods. Histograms indicate expression in the absence (shaded) or presence (non-shaded) of stimulation. Numbers indicate delta mean fluorescence intensity (Δ MFI, stimulated cells minus unstimulated cells) and are representative of five independent experiments. **(b)** TDSN-induced apoptosis in blood DCs was determined by Annexin-V binding following incubation (24 h) in the presence or absence of exogenous IL-12 prior to culture (24 h) with 50% (v/v) peripheral blood mononuclear cell-conditioned supernatant (PBMC-SN) or TDSN (MA11, MB435, MCF7 and SKBR3). Representative dot plots (SSC on y-axis versus apoptosis on x-axis) are shown with numbers indicating the percentage of apoptotic cells. Five independent experiments were performed for which the p -value is indicated.


that reduction in blood DC numbers correlated with disease progression [27]. The resulting immune dysfunction would lead to reduced antitumor immunity [11] and, thus, tumor progression.

The increased pro-apoptotic effect of tumor supernatants demonstrated in this work may have a differential effect on the various DC subsets. In a separate study, we have carefully examined the DC compartment for various immune functions. We identified a population of Lin⁻HLA-DR⁺ cells that is CD11c⁻ and CD123⁻ negative that appears to be particularly resistant to apoptosis induced by supernatants derived from breast (MB231, MA11, MB435, SKBR3 and MCF7) as well as colon (LOVO) cancer cell lines. In contrast, Lin⁻HLA-

DR⁺CD11c⁺CD123⁺ DCs consistently undergo increased levels of apoptosis under the same conditions [28].

We therefore set out to directly confirm the role of tumor products in the induction of blood DC apoptosis in breast cancer. We found that supernatants derived from several breast cancer lines significantly reduced blood DC survival as assessed by Annexin-V, TUNEL and morphological analyses. Our findings on blood DCs confirm previous studies on *in vitro* generated monocyte-derived DCs wherein tumor products (IL-10, prostanoids, gangliosides or ceramides) induced marked levels of apoptosis [4,5,29]. Moreover, in view of the increased level of apoptosis in circulating DCs in patients with cancer described here, it is tempting to speculate that pro-apoptotic

Figure 5



Effect of tumor-derived supernatant (TDSN) and stimulation on expression of Bcl-2. (a) Expression of Bcl-2 in blood dendritic cells (DCs) was determined: *ex vivo* (Fresh); following culture (24 h) in the presence of 50% (v/v) peripheral blood mononuclear cell-conditioned supernatant (PBMC-SN) or TDSN (MA11); or following stimulation (24 h) with a cytokine cocktail (CC), synthetic double-stranded RNA (poly I:C), IL-12 or CD40 ligand (CD40L) prior (24 h) to culture with 50% (v/v) TDSN. Representative histograms (filled) are shown with numbers indicating the mean fluorescence intensity (MFI) of Bcl-2 expression. The unfilled histogram shows staining with isotype control. (b) Summary of Bcl-2 expression data. Results show the average \pm standard error of the mean of five independent experiments for which statistically significant differences compared to fresh cells (*, $p < 0.05$; ***, $p < 0.001$) or after incubation with TDSN (##, $p < 0.01$; ###, $p < 0.001$) are indicated.

tumor products that regularly gain access to the peripheral circulation at high concentrations, such as IL-10 and gangliosides [30,31], could potentially impair viability of blood DCs *in vivo* [2].

From an immunotherapy perspective, our results are relevant in two ways. Firstly, because blood DCs have been proposed for use in cancer immunotherapy [9]. Blood DCs offer the theoretical advantage of being in their natural state of differentiation and presumably capable of stimulating immune responses in a more physiological manner. Apoptotic DCs, however, are ineffective at inducing immunity [32], which may explain, at least in part, the failure of blood DCs from breast cancer patients to capture antigens and generate adequate T-cell responses as described by us (Additional file 1) and others [11,12]. Secondly, because therapeutic DCs would be subject to suppression when re-introduced into patients and, thus, re-exposed to pro-apoptotic products derived from the tumor. In this regard, our results demonstrate that the addition of specific maturation stimuli can protect blood DCs from

tumor-induced apoptosis, thus facilitating their survival and potential effectiveness.

Indeed, by comparing a range of stimuli available for clinical use, including inflammatory cytokines (CC), poly I:C and soluble CD40L, we found that the CC and poly I:C induced robust phenotypic maturation, but failed to protect blood DCs from apoptosis. These results imply that the upregulation of maturation and costimulatory molecules may have only minimal effect on DC survival. In contrast, CD40 stimulation induced strong phenotypic maturation, in addition to augmented IL-12 secretion and protected blood DCs from TDSN-induced apoptosis through sustained expression of the anti-apoptotic molecule Bcl-2. Similarly, exogenous IL-12 protected blood DCs from apoptosis through sustained expression of Bcl-2, suggesting that CD40L-induced protection could be mediated, at least in part, through IL-12 secretion.

Together with Toll-like receptor (TLR) interactions, DC survival induced by CD40L appears to be mediated by the activation

of NF- κ B transcription factor proteins [33]. In a mouse model, the beneficial effect of CD40 ligation has been related to the function of the anti-apoptotic protein Bcl-2, which counter-balances the apoptotic property of various DC maturation stimuli [34]. Our data support and advance this idea in that we identify IL-12 as playing a similar protective role. Further studies on the mechanisms involved in this process will provide better understanding of the homeostatic function of Bcl-2 in DC survival. Interestingly, TRANCE/RANKL, another modulator of NF- κ B, has been implicated in prolonged DC survival [35], particularly after stimulation with CD40L [36]. A recent report correlated a high expression of RANKL in breast tumor cells with a decreased metastatic (bone) phenotype [37]. Considering our data, it is tempting to speculate that the joint effect of RANKL with CD40L leading to prolonged DC survival may prevent tumor growth; an additional argument for the potential benefit of CD40L linked with DC immunotherapy for breast cancer.

In models in which DCs are generated *in vitro*, CD40 stimulation can induce increased DC survival and IL-12 secretion [38], thus promoting IFN- γ production by T-helper cells [39] as well as tumor-specific cytotoxic responses [40]. These data strongly support the use of CD40L conditioning for DCs in cancer immunotherapy. Hitherto, one study has shown the potential of CD40L as an efficient stimulator of professional APC under clinically applicable conditions [41] and two ongoing cancer trials with CD40L-conditioned DCs [42] are awaiting completion. Our results demonstrate that *ex vivo* conditioning of blood DCs with CD40L can protect them from tumor-induced apoptosis and, thus, further support this approach.

Conclusion

Our data demonstrate that in the peripheral circulation, more blood DCs are undergoing apoptosis in patients with breast cancer than in healthy donors. Given that no significant apoptosis was detected in samples from healthy donors, we propose that these cells are programmed *in vivo* to undergo apoptosis by a mechanism related to the presence of tumor products. Indeed, supernatants from breast cancer cell lines induce significant apoptosis of blood DCs *in vitro*. Moreover, we show that loss of expression of the anti-apoptotic molecule Bcl-2 is involved in apoptosis induced by breast cancer cell line supernatants and demonstrate that exogenous conditioning with CD40L (and IL-12) protects blood DCs from apoptosis through sustained expression of Bcl-2. Cumulatively, our findings support the use of exogenous conditioning of DCs to ensure their survival and, thus, may prove crucial in improving the efficacy of DC-based immunotherapies for cancer.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AP-C and JAL conceived and designed the study. AP-C and TM performed the laboratory studies. AP-C, CF and JAL enrolled the patients. AP-C, MAM, CS and JAL analyzed the data. All authors contributed to writing the paper.

Additional files

The following Additional files are available online:

Additional file 1

A figure showing impaired uptake and allo-stimulatory capacity of blood DCs from patients with breast cancer. See <http://www.biomedcentral.com/content/supplementary/bcr1361-S1.pdf>

Acknowledgements

This work was funded by the National Breast Cancer Foundation, Australia. APC had been supported by the University of Queensland International Postgraduate Research and the Paul Mackay Bolton Cancer Research Scholarships. The authors are grateful to Grace Chojnowski and Paula Hall for technical assistance with FACS and MoFlo-sorting. We also thank the Australian Red Cross Blood Service and Sullivan Nicolaides Pathology Laboratories for blood samples and logistic assistance. We are grateful to Amgen for kindly providing CD40L and mostly to our patients and volunteers without whom this study would not have been possible.

References

1. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: **Immunobiology of dendritic cells.** *Annu Rev Immunol* 2000, **18**:767-811.
2. Pinzon-Charry A, Maxwell T, Lopez JA: **Dendritic cell dysfunction in cancer: A mechanism for immunosuppression.** *Immunol Cell Biol* 2005, **83**:451-461.
3. Whiteside TL: **Apoptosis of immune cells in the tumor micro-environment and peripheral circulation of patients with cancer: implications for immunotherapy.** *Vaccine* 2002, **20**(Suppl 4):A46-51.
4. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J: **Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis.** *J Immunol* 2003, **170**:3488-3494.
5. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA: **Ceramide mediates tumor-induced dendritic cell apoptosis.** *J Immunol* 2001, **167**:3773-3784.
6. Kiertscher SM, Luo J, Dubinett SM, Roth MD: **Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells.** *J Immunol* 2000, **164**:1269-1276.
7. Esche C, Lokshin A, Shurin GV, Gastman BR, Rabinowich H, Watkins SC, Lotze MT, Shurin MR: **Tumor's other immune targets: dendritic cells.** *J Leukoc Biol* 1999, **66**:336-344.
8. Thomas R, Davis LS, Lipsky PE: **Isolation and characterization of human peripheral blood dendritic cells.** *J Immunol* 1993, **150**:821-834.
9. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R: **Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study.** *Blood* 1999, **93**:2411-2419.
10. Lopez JA, Hart DN: **Current issues in dendritic cell cancer immunotherapy.** *Curr Opin Mol Ther* 2002, **4**:54-63.

11. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP: **Decreased antigen presentation by dendritic cells in patients with breast cancer.** *Clin Cancer Res* 1997, **3**:483-490.
12. Saththaporn S, Robins A, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, Valerio D, Eremin O: **Dendritic cells are dysfunctional in patients with operable breast cancer.** *Cancer Immunol Immunother* 2004, **53**:510-518.
13. Bell D, Chomarat P, Broyles D, Netto G, Harb GM, Lebecque S, Valladeau J, Davoust J, Palucka KA, Banchereau J: **In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas.** *J Exp Med* 1999, **190**:1417-1426.
14. Coventry BJ, Lee PL, Gibbs D, Hart DN: **Dendritic cell density and activation status in human breast cancer – CD1a, CMRF-44, CMRF-56 and CD-83 expression.** *Br J Cancer* 2002, **86**:546-551.
15. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, Clerici M, Greco M, Villa ML: **Altered maturation of peripheral blood dendritic cells in patients with breast cancer.** *Br J Cancer* 2003, **89**:1463-1472.
16. Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL: **Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma.** *Clin Cancer Res* 2000, **6**:1351-1364.
17. Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL: **Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer.** *Clin Cancer Res* 1999, **5**:1263-1273.
18. Hoffmann TK, Dworacki G, Tsukihito T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL: **Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance.** *Clin Cancer Res* 2002, **8**:2553-2562.
19. Sobin LH, Wittekind C: *International Union Against Cancer: TNM Classification of Malignant Tumors* New York: Wiley-Liss; 2002.
20. Cella M, Salio M, Sakakibara Y, Langen H, Julkunen I, Lanzavecchia A: **Maturation, activation, and protection of dendritic cells induced by double-stranded RNA.** *J Exp Med* 1999, **189**:821-829.
21. Ho CS, Munster D, Pyke CM, Hart DN, Lopez JA: **Spontaneous generation and survival of blood dendritic cells in mononuclear cell culture without exogenous cytokines.** *Blood* 2002, **99**:2897-2904.
22. Pirtskhalaishvili G, Shurin GV, Gambotto A, Esche C, Wahl M, Yurkovetsky ZR, Robbins PD, Shurin MR: **Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice.** *J Immunol* 2000, **165**:1956-1964.
23. Pirtskhalaishvili G, Shurin GV, Esche C, Cai Q, Salup RR, Bykovskaia SN, Lotze MT, Shurin MR: **Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins.** *Br J Cancer* 2000, **83**:506-513.
24. Villadangos JA, Heath WR: **Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: Limitations of the Langerhans cells paradigm.** *Semin Immunol* 2005, **17**:262-272.
25. de la Rosa G, Longo N, Rodriguez-Fernandez JL, Puig-Kroger A, Pineda A, Corbi AL, Sanchez-Mateos P: **Migration of human blood dendritic cells across endothelial cell monolayers: adhesion molecules and chemokines involved in subset-specific transmigration.** *J Leukoc Biol* 2003, **73**:639-649.
26. Lissoni P, Vigore L, Ferranti R, Bukovec R, Meregalli S, Mandala M, Barni S, Tancini G, Fumagalli L, Gianni L: **Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease.** *J Biol Regul Homeost Agents* 1999, **13**:216-219.
27. Pinzon-Charry A, Ho C, Laherty R, Maxwell T, Walker D, Gardiner R, O'Connor L, Pyke C, Schmidt CW, Furnival C, Lopez JA: **A population of HLA-DR+ immature cells accumulate in the blood dendritic cell compartment of patients with different types of cancer.** *Neoplasia* 2005 in press.
28. Pinzon-Charry A, Maxwell T, Prato S, Furnival C, Schmidt CW, Lopez JA: **HLA-DR+ immature cells exhibit reduced antigen presenting cell function but respond to CD40 stimulation.** *Neoplasia* 2005 in press.
29. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ, Pinedo HM, van den Eertwegh AJ, Scheper RJ, de Grujil TD: **Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation.** *J Immunol* 2002, **168**:4333-4343.
30. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, Grosse-Wilde H, Broelsch CE, Gerken G, Cicinnati VR: **Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets.** *Clin Cancer Res* 2004, **10**:7260-7269.
31. Portoukalian J, David MJ, Gain P, Richard M: **Shedding of GD2 ganglioside in patients with retinoblastoma.** *Int J Cancer* 1993, **53**:948-951.
32. Kitajima T, Arizumi K, Bergstresser PR, Takashima A: **Ultraviolet B radiation sensitizes a murine epidermal dendritic cell line (XS52) to undergo apoptosis upon antigen presentation to T cells.** *J Immunol* 1996, **157**:3312-3316.
33. Ouaz F, Arron J, Zheng Y, Choi Y, Beg AA: **Dendritic cell development and survival require distinct NF-kappaB subunits.** *Immunity* 2002, **16**:257-270.
34. Hou WS, Van Parijs L: **A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells.** *Nat Immunol* 2004, **5**:583-589.
35. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, Choi Y: **TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.** *J Exp Med* 1997, **186**:2075-2080.
36. Yu Q, Gu JX, Kovacs C, Freedman J, Thomas EK, Ostrowski MA: **Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals.** *J Immunol* 2003, **170**:1797-1805.
37. Bhatia P, Sanders MM, Hansen MF: **Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma.** *Clin Cancer Res* 2005, **11**:162-165.
38. Esche C, Gambotto A, Satoh Y, Gerein V, Robbins PD, Watkins SC, Lotze MT, Shurin MR: **CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth.** *Eur J Immunol* 1999, **29**:2148-2155.
39. Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, Schuler G: **Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells.** *Eur J Immunol* 1996, **26**:659-668.
40. Terheyden P, Straten P, Brocker EB, Kampgen E, Becker JC: **CD40-ligated dendritic cells effectively expand melanoma-specific CD8+ CTLs and CD4+ IFN-gamma-producing T cells from tumor-infiltrating lymphocytes.** *J Immunol* 2000, **164**:6633-6639.
41. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL: **Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.** *Blood* 2002, **99**:3319-3325.
42. National Cancer Institute's Physician Data Query [\[http://www.cancer.gov/search/clinical_trials\]](http://www.cancer.gov/search/clinical_trials)